FeesSafety
Pluang+

Can-Fite completes dosing in Phase III psoriasis trial; interim results expected Q1 2027

Company Fundamentals
18 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
Can-Fite completes dosing in Phase III psoriasis trial; interim results expected Q1 2027

Can-Fite BioPharma has completed dosing for the first 247 patients in its pivotal Phase III trial of Piclidenoson, an oral drug for moderate-to-severe plaque psoriasis. The interim analysis results, expected in Q1 2027, will assess the drug's efficacy and safety. Piclidenoson targets inflammatory pathways and could offer a convenient, long-term oral treatment with a favorable safety profile. The study follows protocols agreed with FDA and EMA, aiming to meet key efficacy endpoints at Week 16.

Can-Fite BioPharma's Phase III psoriasis study is the subject, with Pluang's Health sector market data providing context. For readers following Health stocks, 64 of 150 priced US stocks rose and 75 fell today. Notable movers include HIMS at USD 17.94 (+2.22%), CTXR at USD 0.53 (+2.16%), and TAK at USD 21.20 (-2.03%). This snapshot is as of Nov 18, 2026 18:11 WIB.

More News

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
49 minutes ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
55 minutes ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgraded Charles Schwab to Strong Buy following strong growth in October 2026. Client assets rose 12% year over year to $13.27 trillion, with core net new assets surging 50% to $66.5 billion, a record for the month. Schwab also opened 4...

Analyst Insights
Bullish
2 hours ago
SDVerse named CES Innovation Awards 2027 Honoree for AI-powered automotive software marketplace.

SDVerse named CES Innovation Awards 2027 Honoree for AI-powered automotive software marketplace.

SDVerse, a B2B automotive software marketplace founded by General Motors, Magna, and Wipro, was honored with a CES Innovation Award 2027 in the Enterprise Tech category. The platform uses AI and standardized technical data to help automakers and supp...

Others
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App